Market Newsdesk

New York, NY, Nov. 13, 2020 (GLOBE NEWSWIRE) — The New York Academy of Medicine (NYAM) has awarded its prestigious 2020 Stephen Smith Medal for Distinguished Contributions in Public Health to the Honorable Andrew M. Cuomo, Governor of the State of New York, in recognition of his leadership of the state during the COVID-19 pandemic. 

Governor Cuomo accepted the award at NYAM’s 173^rd Annual Meeting of the Fellows, which was held virtually on November 12. The event included the induction of 66 new NYAM Fellows and Members, whose names were read by special guests Dr. Howard Zucker, Commissioner of Health for New York State, and Dr. Dave Chokshi, Commissioner of Health for New York City. View the full event video here and the event program here. 

“Every day during the height of the pandemic in New York, we looked to Governor Cuomo for his leadership and compassion as we weathered this extraordinary challenge,” said NYAM President Judith A. Salerno, MD, MS. “His priority was to safeguard the people of New York, and for that we are forever grateful and inspired by his leadership. NYAM is honored to recognize Governor Cuomo’s significant contributions to public health with the 2020 Stephen Smith Medal.”

Michael J. Dowling, President and CEO of Northwell Health, introduced the award. Mr. Dowling served in New York State government for 12 years, including as deputy secretary to former governor Mario Cuomo. 

“During a crisis like this, leadership really, really matters,” Mr. Dowling said. “Leadership that tells the truth. Leadership that uses facts and science to guide decisions. Leadership that builds trust. Leadership that unifies, that brings people together, that focuses people on the central mission of how we deal with issues such as this. … Here in New York, as I know you will all agree with me, we have been very, very fortunate indeed because we have Governor Andrew Cuomo, a model of such leadership.”

”When Governor Cuomo designated University Hospital of Brooklyn as a COVID-only facility, we understood the magnitude of that designation and the trust he placed in our frontline staff,” said NYAM Board Chair and SUNY Downstate Health Sciences University President Wayne J. Riley, MD. “Under Governor Cuomo’s leadership, working with the New York State Department of Health and other partners, we were able to significantly flatten the curve and the spread of the virus by following and adhering to public health guidelines.”

“During these darkest days of COVID, we also saw the light,” Governor Cuomo said in his acceptance speech. “We saw 30,000 retired doctors and nurses return to service to battle the pandemic. We saw 10,000 healthcare professionals from around the country volunteer to come to New York at the height of the pandemic. We saw healthcare professionals become battlefield heroes in saving lives. And we saw the people of New York State rise to the occasion. … I hope and pray a COVID-19-type crisis never happens again, but I believe it will. And your challenge, our challenge, our society’s challenge is to be better prepared for that day before it comes. That’s my goal, I know that’s your goal, and I know that together we will get it done.”

About the Stephen Smith Medal for Distinguished Contributions in Public Health
The New York Academy of Medicine’s medal for lifetime achievement in public health, first awarded in 2005, was named for Stephen Smith, a NYAM Fellow and pioneer in the field of public health. The recipient should have led or significantly contributed to work that effected a significant change in public health policy or practice to improve population health, including work on the broad determinants of health, with a special emphasis on eliminating health disparities. Past recipients include Mary T. Bassett, the Honorable Michael R. Bloomberg, Thomas Frieden, Paula A. Johnson, Michael Marmot and Linda Rosenstock. 

About The New York Academy of Medicine 
The New York Academy of Medicine (NYAM) tackles the barriers that prevent every individual from living a healthy life. NYAM generates the knowledge needed to change the systems that prevent people from accessing what they need to be healthy such as safe and affordable housing, healthy food, healthcare, and more. Through its high-profile programming for the general public, focused symposia for health professionals, and its base of dedicated Fellows and Members, NYAM engages the minds and hearts of those who also value advancing health equity to maximize health for all. For more information, visit nyam.org and follow @nyamnyc on social media.  

Kiri Oliver
The New York Academy of Medicine
212-822-7278
[email protected]

SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the third quarter ended September 30, 2020, and provided an update on recent company developments.

Key recent developments included:

• Significantly advanced the development of AT-301 proprietary nasal spray as potential at-home treatment against COVID-19, with completion of a randomized, placebo controlled, double-blinded Phase 1 study and a preliminary assessment of the blinded data indicating that AT-301 was safe and well tolerated by participants at two different dose levels in both single and multiple dose forms over 14 days.
• Applied for regulatory approval from the European Medical Product Authority to commence a Phase 2 clinical study of Endoxifen in Sweden to reduce mammographic breast density (MBD).
• Announced interim findings following 18 months of an Expanded Access (or “compassionate use”) single-patient study of Endoxifen. The patient in the study had no cancer recurrence and suffered no side effects. Endoxifen did not cause other safety and tolerability concerns in this patient.

“Our COVID-19 nasal spray program has progressed very well during the quarter, with our Phase 1 study of AT-301 nasal spray demonstrating good safety and tolerability at two different dose levels in both single and multiple dose forms over a 14-day trial period,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “We are very encouraged by these preliminary results. In the next 30 days we plan to file a pre-IND meeting request with the FDA and, subject to their input, plan to immediately commence a Phase 2 study, either in the U.S. or abroad, in patients recently diagnosed with COVID-19.

“We believe AT-301 nasal spray is unique among the various therapies under development for COVID-19. While other companies are focused on therapies for patients being treated in hospitals, we are developing AT-301 for at-home use for the vast majority of COVID-19 patients who do not require hospitalization. Although great progress has been made by companies developing vaccines, it has become clear that a vaccine won’t provide a complete solution to the pandemic. No vaccine will be 100 percent effective and surveys have shown that many people won’t take a vaccine even when one becomes available. Similar to the seasonal flu where vaccines don’t provide complete community protection and people also rely on therapies, our AT-301 nasal spray therapy should form an important and necessary component of a comprehensive response to the COVID-19 pandemic,” added Dr. Quay.

Upcoming 2020 milestones include the following:

• File pre-IND meeting request with FDA for AT-301 nasal spray for potential at-home treatment of COVID-19.
• Commence Phase 2 study in Sweden for our Endoxifen to reduce MBD.

September
30, 2020 Financial Results 

For the three and nine months ended September 30, 2020 and 2019, we have no source of sustainable revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were approximately $3,509,000 and $10,382,000 for the three and nine months ended September 30, 2020, respectively, consisting of R&D expenses of approximately $1,659,000 and $4,251,000, respectively, and general and administrative (“G&A”) expenses of approximately $1,850,000 and $6,131,000, respectively. Total operating expenses were approximately $3,298,000 and $14,649,000 for the three and nine months ended September 30, 2019, respectively, consisting of R&D expenses of approximately $1,684,000 and $5,747,000, respectively, and G&A expense of approximately $1,614,000 and $8,901,000, respectively. Total operating expense for the nine months ended September 30, 2020 as compared to the same period in 2019 decreased approximately $4,267,000 or 29% and for the three months ended September 30, 2020 as compared to the same period in 2019 increased approximately $211,000 or 6%.

Research and Development Expenses: R&D expenses for the three months ended September 30, 2020, were approximately $1,659,000, which were comparable to total R&D expenses for the three months ended September 30, 2019, of approximately $1,684,000. R&D expenses for the nine months ended September 30, 2020, were approximately $4,251,000, a decrease of approximately $1,496,000 or 26% from total R&D expenses for the nine months ended September 30, 2019, of approximately $5,747,000. The decrease in R&D expense is attributed primarily to a decrease in stock-based compensation of approximately $2,165,000, which is a non-cash charge, offset by an increase in salaries, professional fees and clinical trials expenses of approximately $669,000, as compared to the same period in 2019. We expect our R&D expenses to increase for the remainder of 2020 as we seek to commence a study of AT-H201, complete our Phase 1 study of AT-301, launch a Phase 2 clinical trial of Endoxifen in women with high breast density, and continue the development of other indications and therapeutics.

General and Administrative Expenses: G&A expenses were approximately $1,850,000 for the three months ended September 30, 2020, an increase of approximately $236,000, or 15% from the total G&A expenses for the three months ended September 30, 2019, of approximately $1,614,000. The $236,000 increase in G&A expenses for the three month period ended September 30, 2020, is mainly attributed to an increase in legal, professional fees and insurance costs. G&A expenses were approximately $6,131,000 for the nine months ended September 30, 2020, a decrease of approximately $2,770,000, or 31% from the total G&A expenses for the nine months ended September 30, 2019, of approximately $8,901,000. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The decrease in G&A expenses for the nine month period ended September 30, 2020, is mainly attributed to a decrease in stock-based compensation expense of approximately $3,535,000, which is a non-cash charge, offset by an increase in legal, professional fees and insurance costs of approximately $765,000 compared to the same period in 2019. 

As of September 30, 2020, the Company had approximately $9.2 million in cash and cash equivalents.

About
Atossa
Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: 866 893-4927
[email protected]

Investor Relations Contact:
Core IR
Office:(516) 222-2560
[email protected]

Source: Atossa Therapeutics, Inc.

ATOSSA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

		As of September 30, 2020				As of December 31,
Assets		(Unaudited)				2019
Current assets
Cash and cash equivalents		$	9,105,950			$	12,581,136
Restricted cash			110,000				110,000
Prepaid expenses			1,484,251				862,344
Research and development tax rebate receivable			439,205				739,656
Other current assets			178,911				26,130
Total current assets			11,318,317				14,319,266
Furniture and equipment, net			25,429				34,350
Intangible assets, net			45,417				68,542
Right-of-use asset			31,279				50,479
Other assets			17,218				17,218
Total Assets		$	11,437,660			$	14,489,855
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable		$	682,612			$	293,171
Accrued expenses			85,173				77,888
Payroll liabilities			752,847				899,420
Lease liability			30,063				39,371
Other current liabilities			14,671				12,892
Total current liabilities			1,565,366				1,322,742
Long term liabilities
Lease liability long term			1,217				11,108
Total Liabilities			1,566,583				1,333,850
Commitments and contingencies
Stockholders’ equity
Preferred stock – $0.001 par value; 10,000,000 shares authorized; 623 and 671 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively			1				1
Additional paid-in capital – Series B convertible preferred stock			622,999				670,999
Common stock – $0.18 par value; 175,000,000 shares authorized; 10,464,250 and 9,130,984 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively			1,883,553				1,643,565
Additional paid-in capital			111,780,197				104,912,480
Accumulated deficit			(104,415,673	)			(94,071,040	)
Total Stockholders’ Equity			9,871,077				13,156,005
Total Liabilities and Stockholders’ Equity		$	11,437,660			$	14,489,855

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA THERAPEUTICS, INC. 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Operating expenses
Research and development		$	1,659,075			$	1,684,215			$	4,250,934			$	5,747,399
General and administrative			1,849,741				1,613,983				6,130,698				8,901,197
Total operating expenses			3,508,816				3,298,198				10,381,632				14,648,596
Operating loss			(3,508,816	)			(3,298,198	)			(10,381,632	)			(14,648,596	)
Other income			17,745				12,284				36,999				26,846
Loss before income taxes			(3,491,071	)			(3,285,914	)			(10,344,633	)			(14,621,750	)
Income taxes			–				–				–				–
Net loss		$	(3,491,071	)		$	(3,285,914	)		$	(10,344,633	)		$	(14,621,750	)
Loss per common share – basic and diluted		$	(0.34	)		$	(0.36	)		$	(1.09	)		$	(1.77	)
Weighted average shares outstanding – basic and diluted			10,162,770				9,130,057				9,496,222				8,283,302

The accompanying notes are an integral part of these condensed consolidated financial statements.

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will host a Preeclampsia Virtual R&D Day on November 20, 2020 from 11 a.m. to 1 p.m. ET (8 a.m. to 10 a.m. PT). Members of Progenity’s senior management team and select guest speakers will provide an in-depth discussion of the company’s ongoing clinical development of the Preecludia™ rule-out test for preeclampsia. Attendees will learn about the pathophysiology of preeclampsia, current clinical management and diagnosis of the condition, its health economic burden, and Progenity’s diagnostic approach.

Interested parties may access a live audio webcast and slides of the presentations on the investor section of Progenity’s website at progenity.com/presentations. Additionally, the live event may be accessed by dialing 833-519-1237 for domestic callers and 914-800-3810 for international callers and entering the conference code: 1190518. A replay of the webcast will be available shortly after the event and can be viewed at the same web link.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.

Investor Contact:

Robert Uhl
Managing Director, Westwicke ICR
[email protected]
(619) 228-5886

Media Contact:

Kate Blom-Lowery
CG Life
[email protected]
(858) 457-2436

Ramsey, NJ, Nov. 13, 2020 (GLOBE NEWSWIRE) — Konica Minolta Business Solutions, U.S.A., Inc., along with Konica Minolta Business Solutions Europe (Konica Minolta), today announced its participation in the IDC European CISO Summit on November 16–17, 2020.

Malware, ransomware attacks, phishing attacks and cyber-attacks can have dramatic consequences for a company’s business activities. Being fully protected requires a corporate culture in which security is deeply rooted. By participating as a GOLD sponsor in the IDC European CISO Summit, Konica Minolta aims to show those who attend its expert talk and several discussion panels how companies can anchor security into their corporate culture. The IDC European CISO Summit is aimed at a selected group of 100+ CISOs from various companies in Europe and serves as an information-sharing forum and networking platform. Owing to the current global situation, IDC has decided to make the summit a virtual event.

“People have a natural sense of security in the physical world when it comes to hygiene, fear of heights, locked doors or strangers. But once online, their level of caution sometimes drops,” said Yoann Fortini, IT Services Go-To-Market Senior Manager, Konica Minolta Business Solutions Europe GmbH. “But the primary point of failure in cyber-attacks is always the end user — the human being. In the end, however, their actions and the consequences they have damage the company as a whole. This is why the digital transformation is first of all a question of people and culture, then only in the second step a question of technology. Security should follow the same path.”

Security should not be seen as a goal in itself, but as a means to ensure business continuity and optimize business performance. Business strategy and security strategy should be connected. CISOs play a significant role here — by shifting their scope from the security team to the company business, by establishing a new agile security leadership style and by directly influencing the future of work.

That is why, during the European CISO Summit, Yoann Fortini will use his 20-minute TechTalk on November 17 at 12:35 p.m. CET to speak about “Corporate culture and security: friends or foes?” He will talk about the fact that companies go through different stages in their digital transformation and that they have to deal with disparate levels of security maturity, but that all these situations have something in common: security is a question of corporate culture. He will therefore emphasize the concept of security culture and that this is not only in the hands of CISOs, but is ultimately the responsibility of everyone in the company. He will also give his top ten tips on how to create a security culture in an organization.

In addition, Yoann Fortini and Gene Abramov, co-founder and CEO of Depth Security, a cybersecurity consulting company acquired by Konica Minolta Business Solutions U.S.A., Inc. in August 2020, will take part in four IDC roundtables “IDC Connect” under the title “Why CISOs are the new business change makers” on November 16 (11:45 a.m. CET and 1:50 p.m. CET) and November 17 (11:30 a.m. CET and 12:55 p.m. CET). They will talk about how the COVID-19 pandemic has confirmed the relevance of CISOs in particular and about security in general for businesses and the economy. In fact, the role of CISOs will be even further expanded in the near future: from user awareness to business strategy, from day-to-day IT security to advanced cyber security policy. Fortini and Abramov will talk about security as a transversal issue that cannot be considered in isolation, but rather forms the basis for all areas of a company in a connected and integrated ecosystem.

“The challenges and opportunities for CISOs and the cybersecurity industry in 2021, particularly with the uncertainty digital transformation places on security posture, require CISOs to be more adaptive than ever,” said Gene Abramov. “The number of decisions – and the speed at which they make them – have significantly increased in the last eight months, and we look forward to sharing our insight from the field to help them navigate what’s ahead.”

Integrated security services from a certified provider

Last but not least, one of the main paradoxes we see today is that security is considered a high priority in most companies, but that companies do not allocate a sufficient portion of their budget to it. Furthermore, the COVID-19 pandemic is regarded as a kind of fire accelerator that has made the vulnerability of many companies visible, especially through decentralized working. With the support of an external provider, businesses can tackle these challenges. “We are well aware that Konica Minolta is not the provider companies first think of when looking for an expert in cyber security — and if they do consider us, it’s for printer security,” Yoann Fortini admits. “But our approach to security is an integrated and holistic one that involves many factors: Through our acquisitions of IT services companies worldwide in recent years, we have brought a high level of external expertise into the company. We have trained our employees on this basis throughout and we have strong partners at hand. This offers our customers — and our main customer base today is SMEs — an integrated, consolidated ecosystem that considers all aspects of the digital workplace, including cyber security, and does so in an easily accessible and reliable manner that is represented globally and available locally at the same time. Our customers receive packaged solutions so that they can concentrate fully on their core business.”

This year, Konica Minolta Business Solutions Europe was awarded ISO 27001 certification for its established Information Security Management System (ISMS). The certificate was issued on the basis of a thorough audit that included in-depth screening of Konica Minolta’s holistic information security approach across all areas, from HR to customer relations, and across all channels, from digital processes to a clean desk policy in the organization. This makes Konica Minolta Business Solutions Europe an ISO 27001-certified supplier.

More information about the IDC European CISO Summit can be found online.

About Konica Minolta Business Solutions U.S.A., Inc.

Konica Minolta Business Solutions U.S.A., Inc. is reshaping and revolutionizing the Workplace of the Future^™ with its expansive smart office product portfolio from IT Services (All Covered), ECM, Managed Print Services and industrial and commercial print solutions. Konica Minolta has been recognized as the #1 Brand for Customer Loyalty in the MFP Office Copier Market by Brand Keys for thirteen consecutive years, and is proud to be ranked on the Forbes 2017 America’s Best Employers list. The World Technology Awards recently named the company a finalist in the IT Software category. Konica Minolta, Inc. has been named to the Dow Jones Sustainability World Index for eight consecutive years and has spent three years on the Global 100 Most Sustainable Corporations in the World list. It partners with its clients to give shape to ideas and work to bring value to our society. For more information, please visit us online and follow Konica Minolta on Facebook, YouTube, Linked In and Twitter.

About Konica Minolta Business Solutions Europe

Konica Minolta Business Solutions Europe GmbH, based in Langenhagen, Germany, is a wholly owned subsidiary of Konica Minolta Inc., Tokyo, Japan. Konica Minolta enables its clients to champion the digital era: with its unique imaging expertise and data processing capabilities, Konica Minolta creates relevant solutions for its customers and solves issues faced by society. As a provider of comprehensive IT services, Konica Minolta delivers consultancy and services to optimise business processes with workflow automation. The company further offers its customers solutions and managed services in the field of IT infrastructure and IT security as well as cloud environments. With regard to its office printing solutions, ‘IDC MarketScape: Worldwide Print Transformation 2020 Vendor Assessment’ stated that Konica Minolta is ‘recognised globally as a leader in print transformation’. As a strong partner for the professional printing market, Konica Minolta offers business consulting, state-of-the-art technology and software and has established itself as the production printing market leader for more than a decade in Europe (InfoSource). In the healthcare sector, Konica Minolta drives digitalisation of clinical workflows and offers a broad range of next-level diagnostic solutions. Its Business Innovation Centre in London and four R & D laboratories in Europe enable Konica Minolta to bring innovation forward by collaborating with its customers as well as academic, industrial and entrepreneurial partners. For its innovative service approach that complements their devices perfectly, Konica Minolta was awarded the prestigious ‘Buyers Lab PaceSetter Award for Serviceability and Support 2020/2021’ from Keypoint Intelligence. Konica Minolta Business Solutions Europe is represented by subsidiaries and distributors in more than 80 countries in Europe, Central Asia, the Middle East and Africa. With approximately 10,000 employees (as of April 2020), Konica Minolta Europe earned net sales of over 2.34 billion in financial year 2019/2020. For more information, please visit the newsroom and follow Konica Minolta on Facebook, YouTube and Twitter @KonicaMinoltaEU.

       

# # # # #

Attachment

• Gene_Abramov_Headshot

Maggie Grande
Konica Minolta Business Solutions U.S.A., Inc.
1-551-500-2659
[email protected]